HARP News and Press, Harpoon Therapeutics Inc. From 07/27/21

Shares of Harpoon Therapeutics Inc. (NASDAQ:HARP) traded at a new 52-week low today of $9.95. Approximately 159,000 shares have changed hands today, as compared to an average 30-day volume of 503,000 shares. Based on a current price of $10.24, Harpoon Therapeutics Inc. is currently 37.8%...

Cullinan is building a unique hub-and-spoke business model in drug development to build more efficient and scalable pipelines. The company has already built out a pipeline of 7 assets and got the model off the ground to prove that they can structure their pipeline based on opportunist...

Photo by goir/iStock via Getty Images Merus jumps on Citi upgrade Merus (MRUS) shares have climbed ~5.4% in early trading after Citi analyst Yigal Nochomovitz upgraded the stock to buy from neutral. The price target of $31.00 per share implies a premium of ~49.9%. Citing dataset pre...

Three TriTAC clinical programs (HPN424, HPN536 and HPN328) have shown tumor size reductions or stable disease, and meaningful treatment duration All four clinical programs demonstrate half-life extension, target engagement and T cell activation Cytokine release syndrome ob...

Gainers: SemiLEDs (LEDS) +66%.Senseonics (SENS) +49%.Windtree Therapeutics (WINT) +38%.MoSys (MOSY) +34%.Ra Medical Systems (RMED) +29%.LightPath Technologies (LPTH) +27%.American Superconductor (AMSC) +26%.Smart Sand (SND) +25%.The9 (NCTY) +24%.Vinco Ventures (BBIG) +22%....

Gainers: Windtree Therapeutics (WINT) +57%, Senseonics (SENS) +38%, Ra Medical Systems (RMED) +22%, Cullinan Oncology (CGEM) +20%, Progenity (PROG) +10%.Losers: Harpoon Therapeutics (HARP) -25%, Purple Biotech (PPBT) -19%, Adamis Pha...

Harpoon Therapeutics shares fall ([[HARP]] -21.6%) after interim data from its ongoing dose-escalation portion of a Phase 1/2a trial for HPN424 in patients with metastatic castration-resistant prostate cancer ((mCRPC)) failed to impress investors.The ongoing dose escalation Phase 1/2a tr...

The ongoing dose escalation Phase 1/2a trial has enrolled 89 patients with progressive, metastatic castration-resistant prostate cancer in 13 cohorts. Safety data continues to show that HPN424 is generally well tolerated, and cytokine-related adverse events have been transient and...

ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...